TrialThe Canadian journal of cardiology2009

A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial.

Olivier F Bertrand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.